FDA Panel Suggests Relaxing Rules on Peptides Amid Controversy

An advisory committee for the Food and Drug Administration has suggested easing regulations on six peptides. This recommendation comes despite concerns from FDA scientists over insufficient data supporting the peptides’ safety and effectiveness. These compounds are promoted for various benefits, including faster healing, youthful skin, and increased lifespan. However, there is a lack of concrete evidence to confirm these claims.

The meeting ended with the suggestion to allow compounding of two additional peptides that remain unproven. This decision, made during a two-day session, sparks questions about the FDA’s commitment to maintaining strict controls to prevent untested drugs from reaching the public.